General Nurse Practitioner News

NP

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ratziu V et al. – Rosiglitazone has a substantial antisteatogenic effect in the first year of treatment without additional benefit with longer therapy despite a maintained effect on insulin sensitivity and transaminase levels. This suggests that improving insulin sensitivity might not be sufficient in NASH and that additional targets of therapy for liver injury should be explored.

Today in Clinical Pharmacology...keeping you current

Valsartan plus hydrochlorothiazide for first-line therapy in hypertension
Expert Review of Cardiovascular Therapy , 12/11/09

Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease
Expert Opinion in Pharmacotherapy, 12/11/09

Zoledronic acid: an unending tale for an antiresorptive agent
Expert Opinion in Pharmacotherapy, 12/11/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address